LabConnect Acquires A4P Bio
BroadOak Capital Partners advised LabConnect on its acquisition of A4P Bio. A4P Bio provides bioanalytical project management solutions and consultancy for clinical trials. The full press release is below. JOHNSON CITY, Tenn., April 22, 2024 /PRNewswire/ — LabConnect has announced the acquisition of A4P Consulting Ltd (A4P), a scientific consultancy company, specializing in bioanalytical and biosample project […]
ZoBio Sells to Oncodesign Services
BroadOak Capital Partners advised ZoBio on the sale of the company to Oncodesign Services. ZoBio is a leading provider of biophysics-based small molecule drug discovery services. The full press release is below. Dijon, France & Leiden, The Netherlands, January 23rd, 2024 – Oncodesign Services (ODS), a leading Contract Research Organization specialized in drug discovery and […]
Pluristyx Closes Major Fundraising Round
BroadOak Capital Partners led Pluristyx’s latest fundraising round, which featured participation from existing investors and key opinion leaders in the life sciences sector. The full press release is below. SEATTLE, WA – December 21, 2023 – Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing […]
celares GmbH Sells to Biosynth
BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH. Celares provides customized bioconjugation solutions for Pharma and IVD industries. The full press release is below. Staad, 11th July 2023 – Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader […]
Genomenon Acquires Boston Genetics
Genomenon, a BroadOak portfolio company and a leader in genomic intelligence, acquired Boston Genetics, a genomics interpretation and curation company. The full press release is below. Genomenon Inc., a leader in Genomic Intelligence, today announced it has acquired Boston Genetics, a genomics interpretation and curation company. By combining Genomenon’s unrivaled AI-powered platform for genomic knowledge […]
Indee Labs Investment from BroadOak BioTools Venture Fund
BroadOak Capital Partners invested in Indee Labs out of its BioTools Venture Fund to support the development of Hydropore, which enables modified immune cell research and development with improved yield and function using a simple workflow, commercial GMP-grade buffers and a small footprint. DeciBio Consulting, a boutique life science strategy consulting firm, partnered with BroadOak […]
Sanguine Biosciences Partners with BroadOak
Sanguine is a leader in custom specimen procurement used by biopharmaceutical companies to accelerate precision medicine and cell & gene therapy R&D. Our investment will help Sanguine expand laboratory operations, leukapheresis offerings, and their patient donor network. The full press release is below. WALTHAM, Mass., Jan. 9, 2023 /PRNewswire/ — Sanguine Biosciences (“Sanguine”), a leader […]
BroadOak Invests in CDI Laboratories
BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing and validation services, to expand and scale antibody biomarker discovery platforms. The full press release is below. BALTIMORE, Jan. 9, 2023 /PRNewswire/ — CDI Laboratories, Inc (“CDI Labs”) announced today that it has received a significant investment from BroadOak Capital Partners (“BroadOak”) […]
PBS Biotech Raises $22M
BroadOak portfolio company PBS Biotech, an innovative manufacturer of single-use bioreactors, has completed a $22 million financing that will be used to improve the company’s products portfolio, expand its process development services capability, and increase customer support for global cell therapy clients. The full press release is below. CAMARILLO, Calif., Jan. 9, 2023 /PRNewswire/ — PBS Biotech […]
FujiFilm Invests in PhenoVista Biosciences
BroadOak portfolio company PhenoVista Biosciences, a leading provider of both custom and off-the-shelf imaging-based assay services, received an investment from Fujifilm’s Life Sciences Corporate Venture Capital Fund to accelerate development of new high-content screening assay services using differentiated iPSCs. The full press release is below. TOKYO, December 14, 2022 – FUJIFILM Corporation (President and CEO, […]